OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Immunology Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
A Sampling of Highlights from the Literature	168
Imaging α-GalCer–Activated iNKT Cells in a Hepatic Metastatic Environment	110
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab	107
Acknowledgment to Reviewers	99
Abstract P042: Chemokine dysregulation creates the immunosuppressive tumor microenvironment and promotes human papillomavirus-associated head and neck cancer	94
A Sampling of Highlights from the Literature	93
A Sampling of Highlights from the Literature	86
Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500	75
Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium	72
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function	67
Revival and Recharacterization of a Preclinical Model of Hormone-Dependent Breast Cancer to Study Immunotherapy	63
Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1–Mediated Immune Evasion in Prostate Cancer	58
CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses	57
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors	56
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches	55
LEF1 Creates Memories in iNKT Cells That Potentiate Antitumor Immunity	53
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer	52
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	52
Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity	51
All Glioblastoma Are Not Equal: Distinct Spatial Immune Profiles BetweenDe Novoand Recurrent Tumors	50
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity	49
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain	49
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation	48
Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment	48
A Single-Cell Analysis of the NK-Cell Landscape Reveals That Dietary Restriction Boosts NK-Cell Antitumor Immunity via Eomesodermin	48

Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy	47
Gefitinib Reverses PD-L1–Mediated Immunosuppression Induced by Long-term Glutamine Blockade in Bladder Cancer	47
P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy	46
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups	46
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors	46
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer	46
Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors	46
Repertoire Remodeling through CD4+ T-cell Depletion	45
Immune-Guided Therapy of COVID-19	45
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment	44
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine	43
Tumor-Associated High Endothelial Venules: Inroads Enabling Immune Control of Cancer Progression	42
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma	41
Host Interactions with Engineered T-cell Micropharmacies	40
Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa	40
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy	39
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer	39
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory	38
T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many	38
Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer	36
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models	36
Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies	36
Clec4A4 Acts as a Negative Immune Checkpoint Regulator to Suppress Antitumor Immunity	35
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway	34
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells	33
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity	33
Augmenting CAR T-cell Functions with LIGHT	33
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma	32
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity	31
Do Not Forget the Granulocytic Compartment’s Role in T cell–Mediated Antitumor Immunity	31
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions	30
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis	30
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens	30
Transforming the Dark into Light: A Siglec-9 Switch	30
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma	30
Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models	28
The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma	28
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes	27
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects	27
Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs	27
HIF1α or HIF2α: Enhancing CD8+ T-cell Fitness for Antitumor Immunity	26
CD8+ T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA PVT1	26
A Sampling of Highlights from the Literature	26
Martin A. “Mac” Cheever, MD: In Memoriam (1944–2021)	26
A Sampling of Highlights from the Literature	26
TIGIT-Fc Promotes Antitumor Immunity	26
A Sampling of Highlights from the Literature	25
Abstract P046: NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer	25
Abstract P013: Germinal center hypoxia in tumor-draining lymph nodes negatively regulates humoral immune responses and affects the activation of tumor-infiltrating T cells	25
A Sampling of Highlights from the Literature	25

Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells	25
Abstract P074: MB097: A therapeutic consortium of bacteria clinically-defined by precision microbiome profiling of immune checkpoint inhibitor patients with potent anti-tumor efficacy in vitro and in	25
Abstract P033: Bone microenvironment-suppressed T cells increase osteoclast formation and the development of osteolytic bone metastases in mice	25
Abstract PR08: Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer	25
Abstract PR05: Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance	24
Abstract IA06: Chimeric antigen receptor macrophages for the treatment of solid tumors	24
Abstract P024: Using innate immune ligands to activate adaptive immune cells for glioblastoma therapy	24
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions	24
Abstract P061: Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits the efficacy of immune checkpoint blockade	23
Abstract P018: Gut microbiota-driven alterations in tumor immunity can modulate the growth of metastatic brain tumors	23
Abstract P035: A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27	23
Abstract P028: Effects of histone deacetylase inhibition on major histocompatibility compatibility complex (MHC) class I expression, growth, and migration of cancer cells	22
Abstract IA21: Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat	22
Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up	22
Abstract P031: Enrichment of photodynamically-primed anti-tumor immune infiltrates in pancreatic cancer: Enabling enhanced immunotherapy	22
A Sampling of Highlights from the Literature	22
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses	21
Antitumor CD4+ T helper 1 cells target and control the outgrowth of disseminated cancer cells	21
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer	21
The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells	21
Abstract IA22: Immunotherapy for melanoma: Checkpoint blockade combinations	21
Abstract P053: Ablation of CCR1 relieves immunosuppression in pancreatic cancer	21
IL-15 complex enhances agonistic anti-CD40 + anti-PDL1 by correcting the T-bet to Tox ratio in CD8+ T cells infiltrating pancreatic ductal adenocarcinoma	20
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis	20
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers	20
In Situ Detection of Individual Classic MHC-I Gene Products in Cancer	20
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells	20
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy	20
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity	19
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner	19
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression	19
VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation	19
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer	19
Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity	19
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions	18
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR	18
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer	18
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer	18
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer	17
Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression	17
CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence	17
Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils	17
Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery	17
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1	17
CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity	16
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells	16
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy	16
IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model	16
The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation	16
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors	16
Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α–STAT3 Axis	16
Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade	16
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	16
Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer	16
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer	16
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade	16
P. gingivalisInfection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer	16
Naturally arising memory-phenotype CD4+ T lymphocytes give rise to multiple helper subsets to contribute to tumor immunity while inhibiting GVHD	15
A Sampling of Highlights from the Literature	15
Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion	15
In situ delivery of Gasdermin E mRNA promotes antitumor immunity via creatine-elicited type Ⅰ interferon signaling in monocytes	15
A Sampling of Highlights from the Literature	15
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer	15
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy	15
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics	14
A Sampling of Highlights from the Literature	14
The Problem with Syngeneic Mouse Tumor Models	14
A Sampling of Highlights from the Literature	14
Abstract PR01: Oncolytic adenoviruses expressing metabolic targets can improve viro-immunotherapy with bispecific T cell engagers through reducing acidosis in an in vitro model	14
Abstract P021: Highly multiplexed spatial analysis of the HCC tumor immune microenvironment using CODEX imaging	14
Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling	14
Abstract P008: Effect of route of Bacillus Calmette Guérin administration on the tumor immune microenvironment in a mouse model of non-muscle invasive bladder cancer	13
Abstract IA05: CAR NK Cells: The future of cancer immunotherapy	13
Abstract P022: Reciprocal influence of immune response and tumor hypoxia during glioblastoma progression	13
Abstract P060: Identification of host-intrinsic resistance mechanisms to immune checkpoint inhibitors (ICI) in Diversity Outbred mice	13
Abstract P048: Steatosis promote liver cancer development by inducing chemokine production from Kupffer cells	13
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response	13
Abstract IA08: Adaptive immune dysregulation in cancer patients with SARS-CoV-2 infection	13
Abstract IA16: Immune suppression in cancer and strategies for its reversal	13
Abstract P064: Dual effect of epigenetic inhibitor and CAR-NK cell therapy in bladder cancer	13

Abstract P065: Effects of targeted radiotherapy on tumor immune landscape in diverse murine tumor models	13
A Sampling of Highlights from the Literature	12
Abstract P062: PI3Kγδ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanized patient-derived xenograft model	12
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1	12
Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer	12
Abstract IA15: Targeting tumor associated macrophages for anti-cancer therapy	12
Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs, but Show Increased T-cell Activation	12
A Sampling of Highlights from the Literature	12
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer	12
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment	12
Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion	12
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect	11
KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer	11
iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma	11
About the Rising Star	11
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function	11
Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation	11
T-cell Receptor Gene Therapy Clinically Targeting aTP53Public Neoantigen	11
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status	11
Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation	11
Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response	11